Skip to main content
. 2015 Aug 19;13:271. doi: 10.1186/s12967-015-0626-6

Table 1.

Relationship between miR-101 expression levels and clinicopathological parameters for the present LSCC cohort

Clinicopathological parameters N (No. of patients) Level of miR-101 expression (T/N ratio)a P value
Patient gender 0.776
 Male 56 0.208 ± 0.056
 Female 24 0.212 ± 0.059
T classification 0.015
 T1–2 40 0.225 ± 0.054
 T3–4 40 0.194 ± 0.055
Lymph node metastasis 0.044
 Negative 45 0.221 ± 0.051
 Positive 35 0.195 ± 0.06
Differentiation 0.096
 Well 54 0.202 ± 0.053
 Moderately/poorly 26 0.225 ± 0.061
Patient age 0.051
 ≥60 years 48 0.212 ± 0.050
 <60 years 32 0.206 ± 0.065
Clinical stage 0.004
 I–II 38 0.228 ± 0.054
 III–IV 42 0.192 ± 0.053
Tobacco exposure 0.638
 Smoker 60 0.208 ± 0.060
 Nonsmoker 20 0.215 ± 0.045
miR-101 levels <0.01
 Low 40 0.166 ± 0.030
 High 40 0.253 ± 0.039

aTumour/normal (T/N) ratio: fold change in miR-101 expression in LSCC tissue to the corresponding adjacent normal tissue. MiR-101 expression was measured by real-time PCR and was normalized to an external control (human U6 gene). Values were quantified using the 2−ΔΔCt method. Values are presented as the mean ± SD.